European Companies Search Engine
EU funding (€2,672,926): Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment Hor1 Sept 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment
Isocitrate dehydrogenase wildtype (IDHwt) glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required. This can only be achieved by focused multi-sectoral collaborations in innovative research disciplines. Overall, GLIORESOLVE will exploit the intractability of GBM to address European applied biomedical research training needs and will train 10 innovative, entrepreneurial doctoral researchers (DRs). The research objectives of GLIORESOLVE are i) to extend immunotherapy options to IDHwt GBM patients and identify novel tumour microenvironment (TME) subtype-specific therapeutic targets, (ii) develop and optimise state of the art pre-clinical models that recapitulate GBM TME-subtypes and (iii) test novel rationally selected (available) drugs / drug combinations for precision treatment of IDHwt GBM based on TME subtype assignment. Cumulatively, the programme seeks to generate sufficient data to support a post-project Phase 2 clinical trial. The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology. Overall GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease. The GLIORESOLVE network addresses current needs in academia and the private sector to train doctoral researchers in an environment that spans multiple disciplines. Thus, GLIORESOLVE DRs will be able to navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.
Funded Companies:
| Company name | Funding amount |
| Arjuna Therapeutics SL | ? |
| BAYER AG | €72,372 |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | €274,370 |
| GENEXPLAIN GmbH | €260,539 |
| Institut du Cerveau et de la Moelle Epiniere | €282,694 |
| Katholieke Universiteit Leuven | €262,620 |
| Luxembourg Institute OF Health | €262,620 |
| MIMETAS B.V. | €274,370 |
| Royal College of Surgeons in Ireland | €286,488 |
| RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG | €434,232 |
| VIB VZW | €262,620 |
Source: https://cordis.europa.eu/project/id/101073386
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Arjuna Therapeutics SL, Ames, Spain.
